Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 4Breast 4Genitourinary 2Thoracic 1Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1Infiltrating Bladder Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 98Specimen Handling 79pembrolizumab 75enzalutamide 63Nivolumab 59Gemcitabine 54Docetaxel 50apalutamide 42Radiosurgery 41Abiraterone Acetate 40Androgen Antagonists 39Prednisone 38Biopsy 37darolutamide 35Cisplatin 35cabozantinib 31Radiotherapy 31Carboplatin 28Pluvicto 27abiraterone 26enfortumab vedotin 24Ipilimumab 24Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 18X-Rays 18Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
pegfilgrastim × Genitourinary × 90 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
237 enrolled
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡